Yadav S K, Jain A K, Tripathi S N, Gupta J P
Indian J Med Res. 1989 Dec;90:496-503.
Among 169 patients with irritable bowel syndrome (IBS), standard therapy (with clidinium bromide, chlordiazepoxide and isaphaghulla), a compound Ayurvedic preparation (with Aegle marmelos correa plus Bacopa monniere Linn) along with a matching placebo were given in a double blind randomised trial for 6 wk. The Ayurvedic preparation in 57 patients was found effective in 64.9 per cent, while standard therapy (60 patients) was useful in 78.3 per cent. Patients on placebo (52 patients) showed improvement in 32.7 per cent only. Ayurvedic therapy was particularly beneficial in diarrhoea predominant form as compared to placebo. The standard therapy was more useful in the painful form of IBS as compared to placebo and Ayurvedic preparation. In gas predominant form the effect of standard as well as Ayurvedic therapy, was similar to placebo. Long-term follow-up (greater than 6 months) showed that both forms of therapy were no better than placebo in limiting the relapse.
在169例肠易激综合征（IBS）患者中，进行了一项为期6周的双盲随机试验，给予标准疗法（含溴化氯氮卓、利眠宁和卵叶车前子）、一种复方阿育吠陀制剂（含印度枳和假马齿苋）以及匹配的安慰剂。结果发现，57例接受阿育吠陀制剂治疗的患者中，64.9%有效；而60例接受标准疗法的患者中，78.3%有效。52例接受安慰剂治疗的患者中，仅有32.7%有所改善。与安慰剂相比，阿育吠陀疗法对以腹泻为主型的患者尤为有益。与安慰剂和阿育吠陀制剂相比，标准疗法对疼痛型IBS患者更有效。在以气体为主型的患者中，标准疗法和阿育吠陀疗法的效果与安慰剂相似。长期随访（超过6个月）显示，两种疗法在限制复发方面并不比安慰剂更好。
